[1]
Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379(22): 2097-107.
[http://dx.doi.org/10.1056/NEJMoa1801174]
[http://dx.doi.org/10.1056/NEJMoa1801174]
[2]
ODYSSEY Outcomes: Alirocumab Cuts CV Events, All-Cause Death Post-ACS. Medscape 2018. Available from:
https://www.medscape.com/viewarticle/893754
[3]
Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376(18): 1713-22.
[http://dx.doi.org/10.1056/NEJMoa1615664]
[http://dx.doi.org/10.1056/NEJMoa1615664]
[4]
Henry CA, Lyon RA, Ling H. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction. Vasc Health Risk Manag 2016; 12: 163-9.
[5]
Milton Packer. Confessions and Omens from the ODYSSEY Trial Milton Packer assesses his predictions on the future lipid research. MEDPAGE TO-DAY 2018. Available from:
https://www.medpagetoday.com/blogs/revolutionandrevelation/71755
[6]
Diaz R, Li QH, Bhatt DL, et al. ODYSSEY OUTCOMES Committees and Investigators. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol 2020; 28(1): 33-43.
[http://dx.doi.org/10.1177/2047487320941987]
[http://dx.doi.org/10.1177/2047487320941987]
[7]
Korman M, Wisløff T. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. Eur Heart J Cardiovasc Pharmacother 2018; 4(1): 15-22.
[http://dx.doi.org/10.1093/ehjcvp/pvx010]
[http://dx.doi.org/10.1093/ehjcvp/pvx010]
[8]
Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts. Discover Thomson Returns Available from:
https://www.reuters.com/article/us-regeneron-pharms-sanofi-fr-cholestero/regeneron-sanofi-cut-heart-drug-price-to-4500-6600-for-express-scripts-idUSKBN1I23FW
[9]
Bhatt DL, Briggs AH, Reed SD, et al. Cost-effectiveness of alirocumab in patients with acute coronary syndromes: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2020; 75(18): 2297-308.
[http://dx.doi.org/10.1016/j.jacc.2020.03.029]
[http://dx.doi.org/10.1016/j.jacc.2020.03.029]
[10]
Shah P. Economic Evaluation of the PCSK9 Inhibitors in prevention of the cardiovascular diseases. Curr Cardiol Rep 2018; 20(7): 51.
[http://dx.doi.org/10.1007/s11886-018-0993-8]
[http://dx.doi.org/10.1007/s11886-018-0993-8]
[11]
Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate. Nasdaq Globe Newswire 2018. Available from:
https://globenewswire.com/news-release/2018/03/10/1420167/0/en/Sanofi-Praluent-alirocumab-significantly-reduced-risk-of-cardiovascular-events-in-high-risk-patients-and-was-associated-with-lower-death-rate.html
[http://dx.doi.org/10.1016/j.jacc.2020.03.029]
[http://dx.doi.org/10.1016/j.jacc.2020.03.029]
Article Metrics
16
1